Moses Huang Selected Research

Solifenacin Succinate

1/2019	Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
12/2017	Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
12/2017	Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
6/2017	Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
5/2017	Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
1/2016	Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
1/2016	Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
8/2015	The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
9/2006	Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Moses Huang Research Topics

Disease

12	Overactive Urinary Bladder (Overactive Bladder) 01/2019 - 09/2006
1	Lower Urinary Tract Symptoms 01/2019
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2019
1	Urinary Retention 06/2017
1	Hypertension (High Blood Pressure) 05/2017
1	Tachycardia (Tachyarrhythmias) 05/2017

Drug/Important Bio-Agent (IBA)

11	mirabegronIBA 01/2019 - 10/2014
9	Solifenacin Succinate FDA Link 01/2019 - 09/2006
4	Muscarinic AntagonistsIBA 01/2019 - 08/2015
1	Tamsulosin (Flomax)FDA LinkGeneric 01/2019
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	TabletsIBA 01/2019
1	Cholinergic Antagonists (Anticholinergics)IBA 05/2017
1	Adrenergic Receptors (Adrenergic Receptor)IBA 05/2017

Therapy/Procedure

3	Therapeutics 12/2017 - 01/2016
1	Drug Therapy (Chemotherapy) 12/2017
1	Bathroom Equipment 12/2017